RPG Life Sciences Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 2026. The certificate, issued by MUFG Intime India Private Limited on April 3, 2026, confirms the company's adherence to dematerialisation requirements and regulatory timelines.

SEBI Compliance Certificate Submission

The company filed the compliance certificate with stock exchanges on April 9, 2026, confirming that all securities received from depository participants for dematerialisation during the quarter ended March 31, 2026, were processed within prescribed timelines. The certificate validates that security certificates received for dematerialisation were properly mutilated and cancelled after verification.

Special Window for Physical Share Transfer

Concurrently, RPG Life Sciences has announced the opening of a special window for shareholders to lodge transfer and dematerialisation requests for physical securities that were sold or purchased prior to April 1, 2019. This initiative follows SEBI's regulatory directive and provides a limited-time opportunity for eligible shareholders to complete pending transfer processes.

The special window has been established pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The company published newspaper advertisements in Business Standard (English) and Mumbai Lakshadeep (Marathi) on April 7, 2026, to inform shareholders about this facility.

Eligibility and Processing Requirements

The special window facility applies to two specific scenarios: where original share transfer requests were not lodged prior to April 1, 2019, and the shareholder holds the original share certificate, or where original requests were lodged but rejected due to document deficiencies. Eligible requests can be submitted to MUFG Intime India Pvt. Ltd., the company's Registrar and Transfer Agent.

All shares processed through this special window will be mandatorily credited in dematerialised form only and will remain under lock-in for one year from the registration date. During the lock-in period, the securities cannot be transferred, lien-marked, or pledged.

RPG Life Sciences has reported encouraging performance indicators for January, with the company's Active Pharmaceutical Ingredients (API) segment showing strong momentum, according to coverage by CNBC-TV18.

API Segment Performance

The pharmaceutical company indicated that January has been a particularly strong month for its API business. This segment represents a crucial component of RPG Life Sciences' overall operations, contributing significantly to the company's revenue streams.

Domestic Portfolio Strength

Alongside the positive API performance, RPG Life Sciences highlighted that its domestic portfolio is demonstrating robust characteristics. The company's domestic operations appear to be gaining traction, suggesting improved market positioning within India's pharmaceutical landscape.

Business Outlook

The combination of strong API performance and a robust domestic portfolio indicates positive momentum across key business verticals for RPG Life Sciences. These developments reflect the company's operational efficiency and market presence in both the API manufacturing and domestic pharmaceutical segments.

The pharmaceutical sector continues to show resilience, with companies like RPG Life Sciences demonstrating strength across multiple business lines, particularly in API manufacturing and domestic market operations.